MacroGenics, Inc. (NASDAQ:MGNX) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Monday, July 31st.
A number of other analysts have also issued reports on the stock. Morgan Stanley dropped their price target on shares of MacroGenics from $24.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, May 8th. Zacks Investment Research upgraded shares of MacroGenics from a “sell” rating to a “hold” rating and set a $19.00 price target for the company in a research note on Tuesday, July 18th. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $32.30.
Shares of MacroGenics (MGNX) traded up 2.59% on Monday, hitting $16.24. 125,238 shares of the stock traded hands. The firm’s 50-day moving average is $17.36 and its 200 day moving average is $18.72. MacroGenics has a 12-month low of $14.36 and a 12-month high of $33.30. The firm’s market cap is $597.60 million.
MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by $0.09. The company had revenue of $1.70 million during the quarter, compared to the consensus estimate of $15.82 million. MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The firm’s quarterly revenue was down 97.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.12 EPS. Equities research analysts forecast that MacroGenics will post ($4.36) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by BNB Daily and is the sole property of of BNB Daily. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.baseball-news-blog.com/2017/08/13/bidaskclub-lowers-macrogenics-inc-mgnx-to-sell-updated.html.
In other MacroGenics news, SVP Jon Marc Wigginton sold 5,000 shares of MacroGenics stock in a transaction on Monday, June 5th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the completion of the transaction, the senior vice president now owns 35,000 shares of the company’s stock, valued at $700,000. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 8.30% of the company’s stock.
Several institutional investors have recently made changes to their positions in MGNX. BB Biotech AG increased its position in shares of MacroGenics by 17.7% in the first quarter. BB Biotech AG now owns 2,260,000 shares of the biopharmaceutical company’s stock valued at $42,036,000 after buying an additional 340,000 shares during the period. Stifel Financial Corp increased its position in shares of MacroGenics by 7.8% in the first quarter. Stifel Financial Corp now owns 20,155 shares of the biopharmaceutical company’s stock valued at $370,000 after buying an additional 1,450 shares during the period. Airain ltd purchased a new position in shares of MacroGenics during the first quarter valued at about $470,000. Hood River Capital Management LLC increased its position in shares of MacroGenics by 17.2% in the first quarter. Hood River Capital Management LLC now owns 563,143 shares of the biopharmaceutical company’s stock valued at $10,474,000 after buying an additional 82,691 shares during the period. Finally, Ameriprise Financial Inc. increased its position in shares of MacroGenics by 1.0% in the first quarter. Ameriprise Financial Inc. now owns 49,059 shares of the biopharmaceutical company’s stock valued at $912,000 after buying an additional 485 shares during the period. 82.34% of the stock is owned by institutional investors.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.